

Subject category: 3. Intracellular signaling

Activation of mitogen-activated protein kinase by hepatocyte growth factor is stimulated by both α_1 - and β_2 -adrenergic agonists in primary cultures of adult rat hepatocytes

Mitsutoshi Kimura*, Hiroshi Okamoto and Masahiko Ogihara

*Corresponding author

Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences,
Josai University. 1-1, Keyakidai, Sakado, Saitama 350-02, Japan

Tel & Fax : 049-271-7316

E-mail: mkimura@josai.ac.jp

Running title: α, β -agonists & HGF-induced MAPK activity

Abstract. We investigated the effects of α_1 - and β_2 -adrenergic agonists on hepatocyte growth factor (HGF)-stimulated mitogen-activated protein kinase (MAPK) isoforms in primary cultures of adult rat hepatocytes. Hepatocytes were isolated and cultured with HGF (5 ng/ml) and/or α - and β -adrenergic agonists. Phosphorylated MAPK isoforms (p42 and p44 MAPK) were detected by Western blotting analysis using anti-phospho-MAPK antibody. The results show that HGF increased phosphorylation of p42 MAPK by 2.2-fold within 3 min. The HGF-induced MAPK activation was abolished by AG1478 treatment (10^{-7} M). The MEK (MAPK kinase) inhibitor PD98059 (10^{-6} M) completely inhibited the HGF-dependent increase in MAPK activity. Phenylephrine (10^{-6} M) and metaproterenol (10^{-6} M) alone had no effect in the absence of HGF, but significantly increased p42 MAPK induction by HGF. Moreover, the cell-permeable cAMP analog, 8-bromo cAMP (10^{-7} M), and phorbol 12-myristate 13 acetate (10^{-7} M) potentiated HGF-induced MAPK phosphorylation. The effects of these analogs were antagonized by the protein kinase A (PKA) inhibitor H-89 (10^{-7} M), and the protein kinase C (PKC) inhibitor sphingosine (10^{-6} M), respectively. These results suggest that direct or indirect activation of both PKA and PKC represent a positive regulatory mechanism for stimulating MAPK induction by HGF.

Keywords: MAP kinase, HGF, α_1 - and β_2 -adrenergic agonists, hepatocytes,

cross-talk

1. Introduction

Hepatocyte growth factor (HGF) has multiple biological activities on a wide variety of cell types (1-4). HGF appears to trigger liver regeneration after partial hepatectomy and acute liver cell necrosis caused by chemicals *in vivo* (5-8). The response of adult rat hepatocytes to HGF has also been investigated extensively with respect to DNA synthesis and proliferation *in vitro*, and HGF is now known to be a potent hepatocyte mitogen (9). More recently, we reported that HGF is able to rapidly stimulate hepatocyte DNA synthesis and proliferation during short-term (e.g., 4 h) culture. In addition, the hepatocyte DNA synthesis and proliferation produced by HGF was inhibited depending on initial plating density. Furthermore, we found that hepatocyte DNA synthesis and proliferation were potentiated by both α_1 - and β_2 -adrenergic agonists (10).

The signal transduction pathways activated in response to HGF in hepatocytes and other cell types have become more clearly understood (3, 11-15). Using specific inhibitors of signal transducers, we pharmacologically demonstrated that receptor tyrosine kinase, phosphoinositide 3-kinase, phospholipase C and ribosomal p70 S6 kinase activities are essential for

HGF-induced DNA synthesis and proliferation in primary cultures of adult rat hepatocytes (10).

In addition, mitogen-activated protein kinase (MAPK) is now known to be activated in response to a large number of mitogenic stimuli, and the enzyme is a key participant in the response to various growth factors and cytokines (12, 16). In order to better understand the HGF-mediated signaling pathway, we investigated whether activation of MAPK isoforms, ERK1 and ERK2, is involved in HGF-induced DNA synthesis and proliferation in primary cultures of adult rat hepatocytes.

Catecholamines (e.g., norepinephrine and its analogs) have been shown to be involved in regulation of liver function (e.g., lipid metabolism, carbohydrate metabolism and cell growth). There are several types of catecholamine receptors, β_1 - and β_2 -receptors, that stimulate adenylate cyclase, while α_2 -receptors inhibit its activity (17). α_1 -Receptors are related to phospholipase C activation and subsequent increases in inositolphosphate turnover and diacylglycerol production (10, 18). Although, some investigators have reported that the α_1 - and β -adrenergic responses are related to adrenergic regulation of carbohydrate metabolism in liver from normal adult rats and cultured hepatocytes (17, 19, 20). There are few studies regarding the adrenergic regulation of MAPK activity induced by growth factors in liver

cells. In the present study, therefore, we examined whether α_1 - and β_2 -adrenergic agonists can modulate HGF-induced MAPK isoform activities. The results obtained here indicate that HGF phosphorylates one of the MAPK isoforms, p42 MAPK, but not p44 MAPK, within 3 min. Moreover, both phenylephrine and metaproterenol potentiated p42 MAPK phosphorylation induction by HGF. The physiological significance of cross-talk between the HGF pathway and α_1 - and β_2 -adrenergic receptor-mediated pathway in regulating hepatocyte proliferation is also discussed.

2. Materials and Methods

2.1 Animals

Male Wistar rats (weight 200-220 g) were obtained from Saitama Experimental Animal Co. (Saitama, Japan). Rats were acclimated in the humidity- and temperature-controlled room for at least 3 days before experimentation, and were fed a standard diet and given tap water *ad libitum*. Rats were handled in accordance with the National Institutes of Health Guidelines for Care and Use of Laboratory Animals.

2.2. Hepatocyte isolation and culture.

Male Wistar rats were anesthetized by intraperitoneal injection of sodium

pentobarbital (45 mg/Kg). Two-step *in-situ* collagenase perfusion was performed to facilitate disaggregation of adult rat livers, as described previously (21). After perfusion, cells were dispersed in Ca²⁺-free Hanks' solution. Cells were then washed three times by slow centrifugation (120 g × 1 min). Hepatocyte viability was monitored by Trypan blue dye exclusion. On average, more than 96% of the cells remained intact.

Isolated hepatocytes were plated onto collagen-coated plastic culture dishes (35 mm diameter) at a density of 3.3×10^4 cells/cm² in Williams' medium E containing 5% bovine calf serum, 0.1 nM dexamethasone for 3 h at 37°C in 5% CO₂ in air. The medium was then changed, and the cells were cultured in serum- and dexamethasone-free Williams' medium E containing HGF (5 ng/ml) with or without α_1 - and β_2 -adrenergic agonists and/or specific effectors or inhibitors of signal transducers for the indicated times at 37°C.

2.3. Measurement of MAPK activity

Phosphorylated MAPK isoforms (P-p42 MAPK, ERK 2; and P-p44 MAPK, ERK 1) were identified by Western blotting analysis using anti-phospho-MAPK (ERK1, 2) monoclonal antibody as described by Towbin et al., (22). Phosphorylated MAPK activity is normalized to the total MAPK. Briefly, cultured hepatocytes were washed once with ice-cold phosphate-buffered saline (pH 7.4) and 0.2 ml of lysis buffer added, after

which the hepatocytes were harvested. After centrifugation at $16,300 \times g$ for 30 min at 4°C , cell lysates were denatured in boiling water for 5 min. Samples of the supernatant (30 μg of protein) were subjected to SDS-PAGE using a 10% acrylamide resolving gel according to the method of Laemmli (23). After electrophoresis, proteins were transferred to Immobilon-P membranes.

For detection of phosphorylated extracellular-regulated protein kinase p44 MAPK (ERK 1) and p42 MAPK (ERK2), the membranes were immersed in Tris-buffered saline (pH 7.4) containing 1% bovine serum albumin. The membranes were then incubated with an antibody (1 $\mu\text{g}/\text{ml}$) against phospho-MAPK and/or MAPK, and were washed as described previously (22). Antibody binding was visualized by incubation with a horseradish peroxidase-conjugated donkey anti-rabbit IgG secondary antibody (1:3000 dilution; 24) followed by enhanced chemiluminescence detection (ECL Kit, Amersham). Densitometry analysis was performed using NIH Image version 1.68 for Macintosh. Data were calculated in arbitrary units and are expressed as means \pm S.E.M.

Cytosolic protein in hepatocytes was quantified by modification of the Lowry procedure with bovine serum albumin as a standard (25).

2.4. Materials

The following reagents were obtained from Sigma Chemical Co. (St. Louis, MO, USA): dexamethasone, aprotinin, aphidicolin, HGF (human recombinant), AG1478 (N-[3-chlorophenyl]-6,7-dimethoxy-4-quinazolinamine), 8-bromo-cAMP, wortmannin, H-89 (N-[2-(p-bromocinnamylamino) ethyl]-5-isoquinolinesulfonamide dihydrochloride), metaproterenol hemisulfate, sphingosine hydrochloride, phenylephrine hydrochloride. PD98059 (2'-amino-3'-methoxyflavone) was obtained from Calbiochem-Behring Corp. (La Jolla, CA, USA). Rapamycin and 12-O-tetradecanoylphorbol-13-acetate (phorbol ester, TPA) were obtained from Research Biochemicals Inc. (Natick, MA, USA). Williams' medium E and newborn calf serum were purchased from Flow Laboratories (Irvine, Scotland). Collagenase (type II) was obtained from Worthington Biochemical Co. (Freehold, NJ, USA). Anti-phospho-p42/p44 MAPK monoclonal antibody and anti-p42/p44 MAPK monoclonal antibody were obtained from Cell Signaling TECHNOLOGY (Danvers, MA, USA). All other reagents were of analytical grade.

2.5. Statistical analysis

Group comparisons were made by ANOVA for unpaired data followed by post hoc analysis using Dunnett's multiple comparison test. Differences

P<0.05 were considered to be statistically significant.

3. Results

3.1. Time course and patterns of MAPK isoform activity stimulated by HGF

It has been reported that MAPK plays an important role in the proliferation of hepatocytes and other cells induced by growth factors and cytokines (26-29). Figure 1A shows the typical detectable pattern of phospho-MAPK on Western blotting analysis. The phosphorylated p42 MAPK band was induced after only 1 min and peaked (about 2-fold increase) between 3 and 5 min after addition of 5 ng/ml HGF, a concentration that stimulated hepatocyte proliferation (Fig. 1B) (10). p44 MAPK was not significantly affected by either medium alone (control) or HGF treatment (Fig. 1C).

3.2. Effects of specific inhibitors of signal transducers on HGF-stimulated MAPK isoform activity

In order to characterize the involvement of MAPK in the mitogenic pathway induced by HGF, we investigated the effects of the receptor tyrosine kinase inhibitor AG1478 (10^{-7} M; 30), the PI3 kinase inhibitor wortmannin (10^{-7} M; 31, 32), the MEK inhibitor PD98059 (10^{-6} M; 27) and the p70S6 kinase inhibitor rapamycin (10 ng/ml; 33) on HGF-induced MAPK activity. As shown in Fig. 2, the phosphorylation of ERK2 induced by HGF (5 ng/ml) at 5 min

was almost completely blocked by AG1478, wortmannin and PD98059. However, rapamycin did not affect the HGF-induced MAPK activity. Phosphorylation of p44 MAPK in the presence of 5 ng/ml HGF was not affected by these inhibitors.

3.3. Activation of p42 MAPK produced by HGF is potentiated by β_2 -adrenergic agonist metaproterenol

The time course of effects of β_2 -adrenergic agonists on MAPK activity induction by 5 ng/ml HGF was investigated using the β_2 -adrenergic agonist metaproterenol. When hepatocytes were stimulated with HGF in the presence of the β_2 -adrenergic agonist metaproterenol (10^{-6} M), the agent caused a more rapid and significant increase in p42 MAPK activity than HGF alone, reaching a peak at 5 min after addition (about 3-fold increase from baseline) and rapidly declining to basal levels within 30 min (Fig. 3A and 3B). In contrast, metaproterenol alone did not significantly stimulate p42 MAPK activity (data not shown). Metaproterenol in the presence of HGF did not significantly stimulate p44 MAPK phosphorylation (Fig. 3C). Therefore, it was found that metaproterenol (10^{-6} M) potentiated the HGF-induced p42 MAPK activity.

3.4. Effect of specific inhibitors of signal transducers on metaproterenol and/or 8-bromo cAMP-induced MAPK isoform activity in the presence of HGF

In order to investigate the potentiating mechanisms for the β_2 -adrenergic receptor/protein kinase A (PKA) pathway in induction of p42 MAPK activity by HGF, we examined the effects of metaproterenol (indirect PKA stimulator; 34) and the cell-permeable cAMP analog 8-bromo cAMP (direct PKA stimulator) on phosphorylation of p42 MAPK induced by HGF. Both metaproterenol- and 8-bromo cAMP-induced potentiation of p42 MAPK phosphorylation in the presence of HGF were almost completely blocked by AG1478, wortmannin and PD98059. However, they were not blocked by rapamycin. In contrast, pretreatment of hepatocytes with the PKA inhibitor H-89 (10^{-7} M; 35) blocked the potentiating effects of metaproterenol or 8-bromo cAMP on the phosphorylation of p42 MAPK in the presence of HGF. Metaproterenol (10^{-6} M) or 8-bromo cAMP (10^{-7} M) alone had no significant effect on the phosphorylation of p44 MAPK and p42 MAPK (Fig. 4)

3.5. Activation of p42 MAPK produced by HGF is potentiated by α_1 -adrenergic agonist phenylephrine

The potentiating effects of α_1 -adrenergic agonists on MAPK pathway induction by 5 ng/ml HGF were investigated with the α_1 -adrenergic agonist phenylephrine. HGF in the presence of phenylephrine (10^{-6} M) caused a more rapid and significant increase in p42 MAPK activity than HGF alone. p42 MAPK activity peaked at 5 min (about 3.5-fold increase from baseline) after

addition and rapidly decreased to basal levels within 30 min (Fig. 5A and 5B). In contrast, phenylephrine alone did not significantly stimulate p42 MAPK activity (data not shown). Phenylephrine (10^{-6} M) in the presence of HGF did not significantly stimulate p44 MAPK phosphorylation (Fig. 5C). The present findings indicate that phenylephrine potentiates HGF-induced p42 MAPK activity.

3.6. Effects of specific inhibitors of signal transducers on α_1 -adrenergic agonist- and/or TPA-induced MAPK isoform activity in presence of HGF

In order to investigate the potentiating mechanism for the α_1 -adrenergic receptor/protein kinase C (PKC) pathway in induction of p42 MAPK activity by HGF, we examined the effects of phenylephrine (indirect PKC activator; 7) and 12-O-tetradecanoylphorbol-13-acetate, (phorbol ester, TPA; direct PKC activator) on the phosphorylation of MAPK isoforms induced by HGF. Both phenylephrine (10^{-6} M)- and TPA (10^{-7} M)-induced potentiation of p42 MAPK phosphorylation in the presence of HGF were almost completely blocked by AG1478, wortmannin and PD98059. However, they were not blocked by rapamycin. In contrast, pretreatment of hepatocytes with the PKC inhibitor sphingosine (10^{-7} M; 36) blocked the potentiative effects of phenylephrine and TPA on the phosphorylation of p42 MAPK induced by HGF. Phenylephrine (10^{-6} M) or TPA (10^{-7} M) alone had no significant effect on the

phosphorylation of p44 MAPK and p42 MAPK (Fig. 6).

4. Discussion

The proliferative pathway by which HGF activates the receptor tyrosine kinase c-Met/MAPK cascade (ERK pathway) has been described in many normal cells and transformed cells (4, 14, 15, 37). The MAPK pathway is one of the most important and intensively studied signaling pathways. However, there are few studies regarding the HGF-induced activation of MAPK isoforms in primary cultured adult rat hepatocytes. Therefore, we investigated the possible roles of the MAPK isoforms induced by HGF in primary cultures of adult rat hepatocytes. As shown in Figs. 1 and 2, we demonstrated that HGF (5 ng/ml) rapidly stimulates p42 MAPK activity, but not p44 MAPK activity. p42 MAPK activity was blocked by the MEK inhibitor PD98059. Moreover, hepatocyte p42 MAPK activity induction by HGF was almost completely blocked by specific inhibitors of signal transducers, such as AG1478 and wortmannin, but not rapamycin (Fig.2). These results suggest that signal transducers such as receptor tyrosine kinase, p42 MAPK and PI3K play an essential role in the mitogenic activity induced by HGF under our experimental conditions. The present results are consistent with reports that p42 MAPK acts upstream of p70S6K and

downstream of receptor tyrosine kinase and PI3K in primary cultures of adult rat hepatocytes (15, 39, 40).

There have been very few studies on the adrenergic agonist-induced regulation of MAPK activity. Thus, we examined whether α_1 - and β_2 -adrenergic agonists modulate the HGF-induced changes in the activity of each MAPK isoform. We found that the HGF-induced hepatocyte p42 MAPK activity was enhanced by metaproterenol (10^{-6} M), a β_2 -adrenergic receptor agonist and an indirect adenylate cyclase activator (Fig. 3) (34). In contrast, metaproterenol alone had no significant effects on hepatocyte MAPK activity in the absence of HGF (Fig. 4). The enhancing effects of metaproterenol in the presence of HGF were inhibited by the PKA inhibitor, H-89 (35), thus suggesting the involvement of PKA in the effects of metaproterenol (Fig. 4). The involvement of PKA in the effects of metaproterenol is supported by our previous results indicating that metaproterenol-induced potentiation of hepatocyte DNA synthesis and proliferation in the presence of HGF (5 ng/mL) was completely inhibited by a specific PKA inhibitor, H-89. (10). However, the role of the second messenger, cAMP, in the control of hepatocyte DNA synthesis and proliferation remains uncertain (39, 40). Cyclic AMP can either stimulate or inhibit DNA synthesis depending on culture conditions (41-44). For example, elevated hepatocyte cAMP levels

have been reported to inhibit HGF-stimulated DNA synthesis and proliferation (3). We demonstrated previously that the cell-permeable cAMP analog, 8-bromo cAMP also enhanced the p42 MAPK activity and hepatocyte proliferation induced by HGF (Fig. 4). These results indicate that the β_2 -adrenergic receptor/cAMP pathway cross-talks with the HGF receptor/MAPK pathway to potentiate hepatocyte growth. Because both metaproterenol- and 8-bromo cAMP-induced potentiation of p42 MAPK activity in the presence of HGF were completely inhibited by AG1478, wortmannin and PD98059, but not rapamycin, β_2 -adrenergic pathway may cross-talk with upstream of ERK2. The point(s) of convergence between the two signaling cascades may be raf or ras, an upstream element of ERK2 (45). A possible scheme for cross-talk between the HGF receptor/MAPK pathway and the β_2 -adrenergic receptor/PKA pathway is shown in Fig.7. The discrepancy between other data and our own is unclear at present. Thus, more detailed mechanisms of the cross-talk between the HGF-signaling pathway and the β_2 -adrenergic receptor/cAMP/PKA pathway should be explored.

While phenylephrine alone had no effect on hepatocyte MAPK activity in the absence of HGF, HGF-induced hepatocyte p42 MAPK was enhanced by phenylephrine, an α_1 -adrenergic agonist (Fig. 6). The enhancing effects of

phenylephrine in the presence of HGF were inhibited by the PKC inhibitor, sphingosine (10^{-6} M; 36), thus suggesting the involvement of PKC in the potentiating effects of the α_1 -adrenoceptor (Fig. 6). The involvement of PKC in the effects of phenylephrine is supported by our previous results indicating that phenylephrine-induced potentiation of hepatocyte DNA synthesis and proliferation in the presence of HGF (5 ng/mL) was completely inhibited by a specific PKC inhibitor, sphingosine. (10). However, the roles of the second messengers, IP_3 and diacylglycerol, in the control of hepatocyte DNA synthesis and proliferation remain uncertain (46). Phorbol ester, 12-O-tetradecanoylphorbol-13-acetate (TPA; 10^{-7} M), is a direct activator of PKC, and can either directly or indirectly stimulate DNA synthesis depending on culture conditions (10, 11, 26, 28). In addition, α_1 -adrenergic receptor-mediated signals may interact with upstream signal transducers, such as the MEK, raf or ras pathways (47), and have a positive influence on normal liver growth and liver regeneration *in vivo* (7, 8, 48, 49). Therefore, the potentiating effects of phenylephrine are likely, at least in part, to cross-talk with the HGF receptor/MAPK pathway; both phenylephrine- and TPA-induced potentiation of p42 MAPK activity induced by HGF were completely inhibited by AG1478, wortmannin and PD98059, but not by rapamycin. Thus, the α_1 -adrenergic pathway may interact with upstream

elements such as raf or ras (45). A possible scheme for cross-talk between the HGF receptor/MAPK pathway and the α_1 -adrenergic receptor/PKC pathway is shown in Fig. 7. More detailed mechanisms of cross-talk between the HGF-signaling pathway and the α_1 -adrenergic receptor/PKC pathway remain to be explored.

In conclusion, the present study demonstrates that the cross-talk signals by extracellular α_1 - and β_2 -adrenoceptor agonists, such as phenylephrine and metaproterenol, potentiate HGF-induced p42 MAPK activity in primary cultured adult rat hepatocytes. The present findings support the notion that endogenous catecholamine-induced potentiation of hepatocyte DNA synthesis and proliferation in the presence of HGF play an important role in the activation of the MAPK cascade during liver regeneration after partial hepatectomy or liver necrosis caused by toxic chemicals *in vivo* (6,7). There are few clear examples of how cells handle or manage various signal pathways. Thus, we should also examine whether there is cross-talk between catecholamine pathways and those of other growth factors (e.g., epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and insulin) in primary cultured hepatocytes.

5. Acknowledgement

This research was partially supported by a Grant-in-Aid for Exploratory Research (No.14771291, 2003) from the Ministry of Education, Science, Sports and Culture.

References

- 1 Strain AJ, Ismail T, Tsubouchi H, Arakaki N, Hishida T, Kitamura N, Daikuhara Y and McMaster P. Native and recombinant human hepatocyte growth factors are highly potent promoters of DNA synthesis in both human and rat hepatocytes. *J. Clin. Invest.* 1991;**87**:1853-1857.
- 2 Nakamura T, Teramoto H and Ichihara A. Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. *Proc Natl Acad.Sci USA.* 1986; **83**:6489-6493.
- 3 Marker A, Galloway JE, Palmer S, Nakamura T, Gould GW, Macsween RN M and Bushfield M. Role of the adenylate cyclase, phosphoinositides C and receptor tyrosyl kinase systems in the control of hepatocyte proliferation by hepatocyte growth factor. *Biochem Pharmacol.*

1992;**44**:1037-1043.

4 Matsumoto K and Nakamura T. Hepatocyte growth factor: renotropic role and potential therapeutics for renal diseases. *Kidney Int.* 2001; **59**:2023-2038.

5 Nakamura T, Nawa K and Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. *Biochem Biophys Res Commun.* 1984; **122**: 1450-1459.

6 Nakamura T, Yoshimoto K, Nakayama Y, Tomita Y and Ichihara A. Reciprocal modulation of growth and differentiated functions of mature rat hepatocytes in primary culture by cell-cell contact and cell membranes. *Proc Natl Acad Sci USA* 1983; **80**:7229-7233.

7 Ishiki Y, Ohnishi H, Muto Y, Matsumoto K and Nakamura T. Direct evidence that hepatocyte growth factor is a hepatotrophic factor for liver regeneration and has a potent antihepatitis effect in vivo. *Hepatology.* 1992; **16**:1227-1235.

- 8 Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA. and Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. *Proc Natl Acad Sci USA*. 2004; **101**:4477-4482.
- 9 Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, Tashiro K and Shimizu S. Molecular cloning and expression of human hepatocyte growth factor. *Nature* 1989;**342**:440-443.
- 10 Kimura M and Ogihara M. Proliferation of adult rat hepatocytes by hepatocyte growth factor is potentiated by both phenylephrine and metaproterenol. *J.Pharmacol.Exp.Ther.* 1997;**282**:1146-1154.
- 11 Osada S, Nakashima S, Saji, S, Nakamura T and Nozawa Y. Hepatocyte growth factor (HGF) mediates the sustained formation of 1, 2-diacylglycerol via phosphatidylcholine-phospholipase in cultured rat hepatocytes. *FEBS Lett.* 1992;**297**:271-274.

- 12 Gines P, Xiaomei L, Zamarripa JL, Brown SE, Wieder ED, Nakamura T, Guzelian PS, Schrier RW, Heasley LE and Nemenoff RA. Tyrosine kinase growth factor receptors or phorbol esters activate mitogen-activated protein kinase in rat hepatocytes. *Hepatology* 1995;**22**:1296-1303.
- 13 Zhang YW and Vande Woude GF. HGF/SF-met signalling in the control of branching morphogenesis and invasion. *J Cell Biochem.* 2003;**88**:408-417.
- 14 Funakoshi H and Nakamura T. Hepatocyte growth factor: from diagnosis to clinical applications. *Clin Chim Acta.* 2003; **327**:1-23.
- 15 Rosario M and Birchmeier W. How to make tubes: signaling by the Met receptor tyrosine kinase. *Trends Cell Biol.* 2003; **13**:328-335.
- 16 Moriuchi A, Hirono S, Ido A, Ochiai T, Nakama T, Uto H, Hori T, Hayashi K and Tsubouchi H. Additive and inhibitory effects of simultaneous treatment with growth factors on DNA synthesis through MAPK pathway and G1 cyclins in rat hepatocytes. *Biochem Biophys Res Commun.* 2001; **280**:368-373.

- 17 Nakamura T, Tomomura A, Kato S, Noda C and Ichihara A. Reciprocal expressions of alpha 1- and beta-adrenergic receptors, but constant expression of glucagon receptor by rat hepatocytes during development and primary culture. *J Biochem (Tokyo)*. 1984;**96**:127-36.
- 18 Dajani OF, Sandnes D, Melien O, Rezvani F, Nilssen LS, Thoresen GH and Christoffersen T. Role of diacylglycerol (DAG) in hormonal induction of S phase in hepatocytes: the DAG-dependent protein kinase C pathway is not activated by epidermal growth factor (EGF), but is involved in mediating the enhancement of responsiveness to EGF by vasopressin, angiotensin II, and norepinephrine. *J Cell Physiol*. 1999;**180**:203-214.
- 19 Refsnes M, Sandnes D, Melien O, Sand TE, Jacobsen S and Christoffersen T. Mechanisms for the emergence of catecholamine-sensitive adenylate cyclase and beta-adrenergic receptors in cultured hepatocytes. Dependence on protein and RNA synthesis and suppression by isoproterenol. *FEBS Lett*. 1983;**164**:291-298
- 20 Okajima F and Ui M. Predominance of beta-adrenergic over alpha-adrenergic receptor functions involved in phosphorylase activation

- in liver cells of cholestatic rats. Arch Biochem Biophys. 1984;**230**:640-651.
- 21 Seglen PO. Preparation of isolated liver cells. Method Cell Biol. 1975;**13**:29-83.
- 22 Towbin H, Staehelin T and Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci U S A. 1979;**76**:4350-4354.
- 23 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;**227**:680-685.
- 24 Kimura M, Osumi S and Ogihara M. Prostaglandin E₂ (EP₁) receptor agonist-induced DNA synthesis and proliferation in primary cultures of adult rat hepatocytes: the involvement of TGF- α . Endocrinology 2001;**142**:4428-4440.
- 25 Lee MB and Paxman S. Modification of the Lowry procedure for the analysis of proteolipid protein. Anal Biochem. 1972;**47**:184-192.

- 26 Adachi T, Nakashima S, Saji S, Nakamura T and Nozawa Y. Roles of prostaglandin production and mitogen-activated protein kinase activation in hepatocyte growth factor-mediated rat hepatocyte proliferation. *Hepatology*. 1995; **21**:1668-1674.
- 27 Alessi DR, Cuenda A, Cohen P, Dudley DT and Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. *J Biol Chem*. 1995;**270**:27489-27494.
- 28 Xiaomei Li PG, Zamarripa JL, Brown SES, Wieder ED, Nakamura T, Guzelian PS, Schrier RW, Heasley LE and Nemenoff RA. Tyrosine kinase growth factor receptors but not seven-membrane-spanning receptors or phorbol esters activate mitogen-activated protein kinase in rat hepatocytes. *Hepatology* 1995;**22**:1296-1303.
- 29 Ostrowski J, Woszczynski M, Kowalczyk P, Trzeciak L, Hennig E and Bomsztyk K. Treatment of mice with EGF and orthovanadate activates cytoplasmic and nuclear MAPK, p70S6k, and p90rsk in the liver. *J Hepatol*. 2000;**32**:965-974.

- 30 Levitzki A and Gazit A. Tyrosine kinase inhibition: an approach to drug development. *Science* 1995;**267**:1782-1788.
- 31 Baggiolini M, Dewald B, Schnyder J, Ruch W, Cooper PH and Payne TG. Inhibition of the phagocytosis-induced respiratory burst by the fungal metabolite wortmannin and some analogues. *Exp Cell Res.* 1987;**169**:408-418.
- 32 Ui M, Okada T, Hazeki K and Hazeki O. Wortmannin as a unique probe for an intracellular signalling protein, phosphoinositide 3-kinase. *TIBS.* 1995;**20**:303-307.
- 33 Chung J, Kuo CD, Crabtree GR and Blenis J. Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases. *Cell* 1992;**69**:1227-1236.
- 34 Ogihara M. Cell-density-dependent expression of the beta-adrenergic response by epidermal growth factor (EGF) in primary cultures of adult rat hepatocytes. *Biol Pharm Bull.* 1996;**19**:752-757.

- 35 Zuscik MJ, Puzas JE, Rosier RN, Gunter KK and Gunter TE. Cyclic-AMP-dependent protein kinase activity is not required by parathyroid hormone to stimulate phosphoinositide signaling in chondrocytes but is required to transduce the hormone's proliferative effect. *Arch Biochem Biophys*. 1994;**315**:352-361.
- 36 Merrill Jr. AH, Nimkar S, Menaldino D, Hannun YA, Loomis C, Bell RM, Tyagi SR, Lambeth JD, Stevens VL, Hunter R and Liotta DC. Structural requirements for long-chain (sphingoid) base inhibition of protein kinase C in vitro and for the cellular effects of these compounds. *Biochemistry* 1989;**28**:3138-3145.
- 37 Seger R and Krebs EG. The MAPK signaling cascade. *FASEB J*. 1995;**9**:726-735.
- 38 Downward J. Regulating S6 kinase, *Nature* 1994;**371**:378-379.
- 39 Kimura M and Ogihara M. Density-dependent proliferation of adult rat hepatocytes in primary culture induced by epidermal growth factor is potentiated by cAMP-elevating agents. *Eur J Pharmacol*. 1997;

324:267-276.

- 40 Kimura M and Ogihara M. Proliferation of adult rat hepatocytes in primary culture induced by insulin is potentiated by cAMP-elevating agents. *Eur J Pharmacol.* 1997;**327**:87-95.
- 41 Bronstad GO, Sand TE and Christoffersen T. Bidirectional concentration-dependent effects of glucagon and dibutyryl cyclic AMP on DNA synthesis in cultured adult rat hepatocytes. *Biochim Biophys Acta.* 1983;**763**:58-63
- 42 Mahler SM and Wilce PA. Desensitization of adenylate cyclase and cyclic AMP flux during the early stages of liver regeneration. *J Cell Physiol.* 1988;**136**:88-94.
- 43 Vintermyr OK, Mellgren G, Boe R and Doskeland TO. Cyclic adenosine monophosphate acts synergistically with dexamethasone to inhibit the entrance of cultured adult rat hepatocyte into s-phase with a note on the use of nucleolar and extranucleolar [³H]thymidine labelling patterns to determine rapid changes in the rate of onset of DNA replication. *J Cell*

Physiol. 1989;**141**:371-382.

- 44 Refsnes M, Thoresen GH, Sandnes D, Dajani OF, Dajani L and Christoffersen T. Stimulatory and inhibitory effects of catecholamines on DNA synthesis in primary rat hepatocyte cultures: Role of Alpha₁-and beta-adrenergic mechanisms. J Cell Physiol. 1992;**151**:164-171.
- 45 Gines P, Li X, Brown SE, Nakamura T, Guzelian PS, Heasley LE, Schrier RW and Nemenoff RA. Inhibitory actions of cyclic adenosine monophosphate and pertussis toxin define two distinct epidermal growth factor-regulated pathways leading to activation of mitogen-activated protein kinase in rat hepatocytes. Hepatology 1996;**23**:1167-1173.
- 46 Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993;**361**:315-325.
- 47 Spector MS, Auer KL, Jarvis WD, Ishac EJ, Gao B, Kunos G and Dent P. Differential regulation of the mitogen-activated protein and stress-activated protein kinase cascades by adrenergic agonists in quiescent and regenerating adult rat hepatocytes. Mol Cell Biol. 1997;**17**:3556-3565.

48 Morgan NG, Blackmore PF, Exton JH. Age-related changes in the control of hepatic cyclic AMP levels by alpha 1- and beta 2-adrenergic receptors in male rats. *J Biol Chem.* 1983;**258**:5103-5109

49 Michalopoulos GK and DeFrances MC. Liver regeneration. *Science* 1997;**276**:60-66.

Figure legends

Fig. 1. Time course and patterns of MAPK isoform activity induced by HGF.

Isolated hepatocytes cultured for 3 h were washed and incubated in either the absence (control; C: medium alone) or presence of 5 ng/ml HGF for the indicated times at 37°C. Phosphorylated MAPK isoforms (P-p42/P-p44 MAPK) were identified using anti-phospho MAPK antibody, as described in Materials and Methods. Intensity of the M_r 44-kDa and 42-kDa bands corresponding to phosphorylated p44 MAPK and p42 MAPK was normalized to total MAPK (p42/p44 MAPK (p42/p44 MAPK). A; typical Western blotting band, phosphorylated p42 /p44MAPK (P-p42/P-p44 MAPK), total p42/p44 MAPK (p42/p44 MAPK); B: time-course of phosho-p42 MAPK (ERK2) activity; C: time-course of phosho-p44 MAPK (ERK1) activity. Results are expressed as a percentage of the respective control value (mean \pm SEM of three experiments). * P <0.05; ** P <0.01 compared with respective controls.

Fig. 2. Effects of specific inhibitors of signal transducers on MAPK isoform activity induction by HGF.

Hepatocytes were stimulated with HGF (5 ng/ml) in the presence of specific inhibitors of signal transducers, such as AG1478 (10^{-7} M), PD98059 (10^{-6} M), wortmannin (10^{-7} M) and rapamycin (10 ng/ml). Phosphorylated MAPK

isoforms (p44 kDa as ERK 1 and p42 kDa as ERK 2) were determined after incubation for 5 min with the test agents. Phosphorylated MAPK isoforms were identified using anti-phospho-MAPK antibody as described in Materials and Methods. Results are expressed as percentage of the respective control value (mean \pm SEM of three experiments). $**P<0.01$ compared with respective controls (HGF alone).

Fig. 3. Effects of metaproterenol on time course and patterns of MAPK isoform activity induced by HGF.

Hepatocytes were stimulated with HGF (5 ng/ml) in the absence or presence of metaproterenol (10^{-6} M). Phosphorylated MAPK isoforms and/or total MAPK (A: typical Western blotting band; B: p42 MAPK; and C: p44 MAPK) were identified using anti-phospho-MAPK antibody and/or anti-MAPK, as described in Materials and Methods. Results are expressed as a percentage of the respective control value (mean \pm SEM of three experiments). $*P<0.05$; $**P<0.01$ compared with respective controls. H: HGF; Meta: metaproterenol.

Fig. 4. Effects of specific inhibitors of signal transducers on metaproterenol and/or 8-bromo cAMP-induced MAPK isoform activity in the presence of HGF.

Hepatocytes were stimulated with HGF (5 ng/ml) plus metaproterenol (10^{-8} - 10^{-6} M), and/or 8-bromo cAMP (10^{-9} - 10^{-7} M) in the presence of specific signal transducer inhibitors such as AG1478 (10^{-7} M), PD98059 (10^{-6} M), wortmannin (10^{-7} M), rapamycin (10 ng/ml) and H-89 (10^{-7} M). Phosphorylated MAPK isoforms (ERK 1 and ERK 2) were determined after incubation for 5 min with the test agents. Phosphorylated MAPK isoforms (ERK 1 and ERK 2) were identified using anti-phospho-MAPK antibody, as described in Materials and Methods. Results are expressed as a percentage of the respective control value (mean \pm SEM of three experiments). * P <0.05; ** P <0.01 compared with respective controls (HGF alone).

Fig. 5. Effects of phenylephrine on time course and patterns of MAPK isoform activity induced by HGF.

Hepatocytes were stimulated with HGF (5 ng/ml) in the absence or presence of phenylephrine (10^{-6} M). Phosphorylated MAPK (A: typical Western blotting band; B: p42 MAPK; and C: p44 MAPK) were identified using anti-phospho-MAPK antibody and/or anti-MAPK, as described in Materials and Methods. Results are expressed as a percentage of the respective control value (mean \pm SEM of three experiments). * P <0.05; ** P <0.01 compared with respective controls. H: HGF; Phen: phenylephrine.

Fig. 6. Effects of specific inhibitors of signal transducers on phenylephrine and/or TPA-induced MAPK isoform activity in the presence of HGF.

Hepatocytes were stimulated with HGF (5 ng/ml) plus phenylephrine (10^{-8} - 10^{-6} M), and/or TPA (10^{-9} - 10^{-7} M) in the presence of specific inhibitors of signal transducers, such as AG1478 (10^{-7} M), PD98059 (10^{-6} M), wortmannin (10^{-7} M), rapamycin (10 ng/ml) and sphingosine (10^{-7} M). Phosphorylated MAPK isoforms (ERK 1 and ERK 2) were determined after incubation for 5 min with test agents. Phosphorylated MAPK isoforms (ERK 1 and ERK 2) were identified using anti-phospho-MAPK antibody, as described in Materials and Methods. Results are expressed as a percentage of the respective control value (mean \pm SEM of three experiments). * P <0.05; ** P <0.01 compared with respective controls (HGF alone).

Fig. 7. Possible model for cross-talk between HGF receptor/MAPK pathway and α_1 - or β_2 -adrenergic receptor-mediated pathways.

Abbreviations: HGF, hepatocyte growth factor; TK, receptor tyrosine kinase; AC, adenylate cyclase; PLC, phospholipase C; PI3K, phosphatidylinositol 3-kinase; MEK, MAP kinase kinase; MAPK, mitogen-activated protein kinase; p70S6K, p70 ribosomal protein S6 kinase; PKA, protein kinase A; PKC, protein kinase C; DG, diacylglycerol; IP₃, inositol 1, 4, 5-triphosphate.




Fig. 1 Kimura M, Okamoto H and Ogihara M




Fig. 2 Kimura M, Okamoto H and Ogihara M




Fig. 3 Kimura M, Okamoto H and Ogiyara M




Fig. 4 Kimura M, Okamoto H and Ogihara M




Fig. 5 Kimura M, Okamoto H and Ogihara M




Fig. 6 Kimura M, Okamoto H and Ogihara M




Fig. 7 Kimura M, Okamoto H and Ogiyara M